Sinco Pharmaceuticals Holdings Limited (stock code: 06833) published its Monthly Return for the period ended 31 January 2026, confirming that its authorized share capital remained at 10,000,000,000 ordinary shares at a par value of HKD 0.0001 each, totaling HKD 1,000,000.

The announcement indicates that 2,032,890,585 ordinary shares were issued and no treasury shares were held as of 31 January 2026. No changes occurred in the number of issued shares, and the public float requirement was met.

In the share option scheme that became effective on 26 May 2025, there were no outstanding or newly granted share options during the month. Meanwhile, up to 203,289,058 shares remain issuable under the scheme. No warrants, convertibles, or other agreements to issue new shares were noted, and no treasury share transactions occurred during the month.